不同剂量华法林对心脏瓣膜置换术后患者抗凝的临床观察

Clinical observation of different doses of warfarin on anticoagulation for patients with cardiac valvular replacement

目的观察心脏瓣膜置换术患者应用华法林抗凝的临床疗效。方法 70例心脏瓣膜置换术患者,随机分为试验组和对照组,各35例。试验组应用低剂量华法林抗凝维持国际标准化比值(INR)在1.5~2.0,对照组应用标准剂量华法林抗凝维持INR在2.0~3.0。观察两组患者INR的不良事件发生率。结果试验组患者的不良反应发生率为0例(0),对照组患者为3例(8.5%),两组比较差异有统计学意义(P<0.05)。结论对于心脏瓣膜置换术后患者应用低剂量的华法林与标准剂量可以减少患者的出血风险。

Objective To observe the clinical effect of patients with cardiac valvular replacement treated with warfarin for anticoagulation. Methods A total of 70 cardiac valvular replacement patients were randomly divided into experimental group and control group, with 35 cases in each group. The experimental group received low dose of warfarin anticoagulation maintaining international standardization ratio (INR) in 1.5~2.0, and the control group received standard dose of warfarin anticoagulation maintaining INR in 2.0~3.0. Incidence of adverseevents in INR was observed in two groups. Results The experimental group had incidence of adverse reactionsas 0 case (0), while 3 cases (8.5%) in the control group. Their difference had statistical significance (P<0.05).Conclusion Low dose and standard dose of warfarin can reduce risk of hemorrhage in patients for patients with cardiac valvular replacement.